BRNS

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change +0.0925
Percentage change 11.28	%

Peers: AMGN REGN GILD BIIB VRTX INCY NBIX PBYI FATE MDGL

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.49	Insider Own	7.52%	Shs Outstand	39.54M	Perf Week	-10.54%
Market Cap	36.08M	Forward P/E	-	EPS next Y	-1.80	Insider Trans	0.00%	Shs Float	36.57M	Perf Month	-34.82%
Income	-58.07M	PEG	-	EPS next Q	-0.46	Inst Own	17.08%	Short Float	0.04%	Perf Quarter	-27.58%
Sales	15.12M	P/S	2.39	EPS this Y	17.98%	Inst Trans	4.39%	Short Ratio	0.28	Perf Half Y	-50.14%
Book/sh	4.02	P/B	0.23	EPS next Y	-14.66%	ROA	-27.74%	Short Interest	0.01M	Perf Year	-70.56%
Cash/sh	2.68	P/C	0.34	EPS next 5Y	-	ROE	-32.74%	52W Range	0.80 - 4.16	Perf YTD	-75.27%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-34.16%	52W High	-78.06%	Beta	-0.71
Dividend TTM	-	Quick Ratio	8.93	Sales past 5Y	4086.64%	Gross Margin	61.41%	52W Low	13.95%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	8.93	EPS Y/Y TTM	26.58%	Oper. Margin	-427.02%	RSI (14)	42.21	Volatility	15.51% 15.43%
Employees	130	Debt/Eq	0.08	Sales Y/Y TTM	106.80%	Profit Margin	-384.00%	Recom	1.00	Target Price	7.25
Option/Short	No / Yes	LT Debt/Eq	0.07	EPS Q/Q	42.72%	Payout	-	Rel Volume	0.42	Prev Close	0.82
Sales Surprise	-	EPS Surprise	52.63%	Sales Q/Q	-	Earnings	Nov 06 BMO	Avg Volume	48.93K	Price	0.91
SMA20	-3.01%	SMA50	-22.82%	SMA200	-46.67%	Trades		Volume	20,486	Change	11.28%

Date	Action	Analyst	Rating Change	Price Target Change
May-25-21	Initiated	William Blair	Outperform
May-25-21	Initiated	Morgan Stanley	Overweight	$22
May-25-21	Initiated	Jefferies	Buy	$28
May-24-21	Initiated	H.C. Wainwright	Buy	$25

Nov-25-24 04:01PM	Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer (GlobeNewswire) +8.91%
Nov-15-24 11:02AM	Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion (GlobeNewswire) -29.70%
11:01AM	Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B (GlobeNewswire)
Nov-06-24 08:00AM	Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results (GlobeNewswire) +10.57%
Oct-31-24 08:00AM	Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 The Liver Meeting and Attendance at November Conferences (GlobeNewswire)
08:00AM	Loading…
Oct-01-24 08:00AM	Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer (GlobeNewswire)
Sep-24-24 08:00AM	Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease (GlobeNewswire)
Aug-08-24 08:00AM	Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results (GlobeNewswire)
Aug-01-24 08:00AM	Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors (GlobeNewswire)
Jun-12-24 04:01PM	Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections (GlobeNewswire)
Jun-06-24 11:15AM	Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B (GlobeNewswire)
May-22-24 08:00AM	Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024 (GlobeNewswire) +6.91%
May-13-24 01:53PM	BRNS Stock Earnings: Barinthus Biotherapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments (GlobeNewswire)
May-01-24 07:00AM	Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer (GlobeNewswire) +7.32%
04:10PM	Loading…
Apr-18-24 04:10PM	Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections (GlobeNewswire) -7.38%
Mar-20-24 01:52PM	BRNS Stock Earnings: Barinthus Biotherapeutics Beats EPS for Q4 2023 (InvestorPlace)
08:15AM	Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments (GlobeNewswire)
Jan-05-24 04:01PM	Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones (GlobeNewswire)
Dec-21-23 07:31AM	New partnership aims to advance vaccine against MERS coronavirus (GlobeNewswire)
Nov-09-23 04:24PM	Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD (GlobeNewswire) +13.24% -7.08%
04:01PM	Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
04:01PM	Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting (GlobeNewswire)
Nov-06-23 09:05AM	Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer (GlobeNewswire) +11.36%
Oct-04-23 06:23AM	Kymera Therapeutics, Inc. (KYMR) Soars 14.3%: Is Further Upside Left in the Stock? (Zacks) +10.29%
Sep-13-23 08:00AM	Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023 (GlobeNewswire)
Aug-10-23 08:00AM	Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Aug-09-23 07:37AM	Vaccitech (NASDAQ:VACC) shareholders have endured a 50% loss from investing in the stock a year ago (Simply Wall St.) -5.17%
Jul-19-23 08:34PM	Tarsus Pharmaceuticals, Inc. (TARS) Surges 7.8%: Is This an Indication of Further Gains? (Zacks)
Jun-29-23 07:11AM	Vaccitech (NASDAQ:VACC) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
06:49AM	Loading…
06:49AM	Daily Vickers Top Buyers & Sellers for 06/29/2023 (Argus Research)
Jun-21-23 09:03AM	Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B (GlobeNewswire)
07:30AM	Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody (GlobeNewswire)
Jun-12-23 07:30AM	Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy (GlobeNewswire)
May-19-23 06:04AM	Newsflash: Vaccitech plc (NASDAQ:VACC) Analysts Have Been Trimming Their Revenue Forecasts (Simply Wall St.)
May-12-23 08:00AM	Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
May-05-23 07:33AM	Revenues Working Against Vaccitech plc's (NASDAQ:VACC) Share Price (Simply Wall St.)
Apr-17-23 09:00AM	Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile (GlobeNewswire)
Apr-05-23 01:40PM	7 Thrilling Biotech Stocks for Aggressive Investors to Buy (InvestorPlace)
Mar-28-23 08:00AM	Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B (GlobeNewswire) -9.72%
Mar-24-23 08:06AM	Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments (GlobeNewswire) +12.49%
Mar-20-23 12:44PM	Vaccitech Says Prime-boost Vaccine Study Data In Women With Low-grade HPV Lesions Is 'Promising Step In Right Direction' (Benzinga)
08:00AM	Vaccitechs VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions (GlobeNewswire)
Mar-16-23 06:47AM	Owning 39% shares,institutional owners seem interested in Vaccitech plc (NASDAQ:VACC), (Simply Wall St.)
Mar-01-23 06:01AM	11 High Growth UK Stocks to Buy (Insider Monkey) +12.90%
Jan-30-23 08:00AM	Vaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Jan-13-23 05:24AM	Vaccitech (NASDAQ:VACC) adds US$10m to market cap in the past 7 days, though investors from a year ago are still down 73% (Simply Wall St.)
Nov-21-22 10:31AM	Vaccitech to Host KOL Webinar on the SNAPvax Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases (GlobeNewswire)
Nov-13-22 07:29AM	Vaccitech Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-10-22 04:30PM	Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments (GlobeNewswire) +5.38%
Nov-09-22 08:00AM	Vaccitech to Present at Upcoming November Investors Conferences (GlobeNewswire)
Nov-07-22 08:00AM	Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B (GlobeNewswire)
Nov-02-22 08:00AM	Vaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® Providing Update on the Phase 1b/2a Study of VTP-300 (GlobeNewswire)
Oct-31-22 08:00AM	Vaccitech Doses First Patients in HBV003, a Phase 2b Clinical Trial of VTP-300 immunotherapeutic candidate for Chronic HBV Patients (GlobeNewswire)
Oct-27-22 07:00AM	Publication in Cell Shows That Vaccitechs SNAPvax Has the Potential to Treat Cancer by Reversing Suppressive Tumor Microenvironment with Novel Vax-Innate Paradigm (GlobeNewswire)
Oct-06-22 11:45AM	Vaccitech plc (NASDAQ:VACC) stock most popular amongst individual investors who own 33%, while private equity firms hold 31% (Simply Wall St.)
Oct-03-22 04:30PM	Vaccitech to Present at Upcoming October Investor & Scientific Conferences (GlobeNewswire)
Sep-20-22 04:30PM	Vaccitech Promotes Gemma Brown as Chief Financial Officer (GlobeNewswire)
Sep-07-22 04:01PM	Vaccitech to Present at Upcoming September Investors Conferences (GlobeNewswire)
12:00PM	Vaccitech PLC Sponsored ADR (VACC) Upgraded to Buy: Here's Why (Zacks)
Aug-15-22 06:14AM	New Forecasts: Here's What Analysts Think The Future Holds For Vaccitech plc (NASDAQ:VACC) (Simply Wall St.)
Aug-11-22 09:14AM	Vaccitech plc Beat Analyst Profit Forecasts, And Analysts Have New Estimates (Simply Wall St.) -7.13%
Aug-09-22 04:15PM	Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments (GlobeNewswire) +5.05% -7.21%
Jul-07-22 04:15PM	Vaccitech to Present at the William Blair Biotech Focus Conference 2022 (GlobeNewswire)
Jul-03-22 10:08AM	Investors one-year losses grow to 69% as the stock sheds US$48m this past week (Simply Wall St.)
Jun-22-22 01:34PM	Vaccitech's Vaccine Induced Sustained Reductions In Hepatitis B Associated Antigens (Benzinga) +36.18%
06:00AM	Vaccitechs VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1 (GlobeNewswire)
Jun-06-22 04:15PM	Vaccitech to Present at the Jefferies Healthcare Conference (GlobeNewswire) +12.41%
07:32AM	Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus (GlobeNewswire)
May-20-22 11:30AM	Vaccitech to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +7.23%
May-19-22 06:32AM	Broker Revenue Forecasts For Vaccitech plc (NASDAQ:VACC) Are Surging Higher (Simply Wall St.) -7.61%
May-11-22 04:15PM	Vaccitech Reports First Quarter 2022 Financial Results and Recent Corporate Developments (GlobeNewswire) -21.82% -5.21%
Apr-29-22 10:30AM	What Type Of Shareholders Own The Most Number of Vaccitech plc (NASDAQ:VACC) Shares? (Simply Wall St.) +8.98%
Apr-06-22 04:15PM	Vaccitech Announces Notification of Milestone and Royalty Revenue Relating to Sales of Vaxzevria® (GlobeNewswire) +7.69%
Mar-25-22 07:15AM	Vaccitech Reports Full-Year 2021 Financial Results and Recent Corporate Developments (GlobeNewswire) -14.26%
Mar-07-22 08:00AM	Vaccitech to Present at the Barclays Global Healthcare Conference 2022 (GlobeNewswire) -8.52%
Jan-21-22 03:41AM	DeepMind Co-Founder Suleyman Exits Google for VC Firm Greylock (Bloomberg)
Jan-18-22 03:00AM	Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine (GlobeNewswire)
Jan-13-22 04:34PM	Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics Landscape (GlobeNewswire) -12.33%
Jan-10-22 10:00AM	Wall Street Analysts Believe Vaccitech PLC Sponsored ADR (VACC) Could Rally 113%: Here's is How to Trade (Zacks)
Dec-13-21 04:05PM	Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines (GlobeNewswire)
Dec-07-21 08:00AM	Vaccitech reports promising interim efficacy analysis in Phase 1b/2a clinical study in chronic HBV (GlobeNewswire)
Nov-24-21 09:20AM	Vaccitech to Participate at The 33rd Annual Virtual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-12-21 08:00AM	Vaccitechs VTP-300 was Well-Tolerated and Induced T cells against all targeted HBV antigens in both Healthy Volunteers and Patients with Chronic HBV Infection in Interim Analyses (GlobeNewswire)
07:00AM	Vaccitech Reports Third Quarter 2021 Financial Results and Recent Corporate Developments (GlobeNewswire)
Nov-10-21 08:00AM	Vaccitech to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-04-21 04:00AM	Vaccitech Announces Publication of Second Phase 1 Clinical Trial Results of ChAdOx1 Vaccine in Development for the MERS Coronavirus (GlobeNewswire)
Oct-28-21 01:23PM	What Kind Of Shareholders Hold The Majority In Vaccitech plc's (NASDAQ:VACC) Shares? (Simply Wall St.)
Oct-18-21 08:00AM	Vaccitech Announces Data Presentations at AASLDs Liver Meeting® 2021 (GlobeNewswire)
Oct-13-21 08:00AM	Vaccitech to Present an Update on Its Chronic HBV Infection Immunotherapeutic Program at The World Vaccine Congress Europe (GlobeNewswire)
Sep-13-21 12:38PM	Taxpayer takes stake in Oxford vaccine co-creator (The Telegraph)
Sep-09-21 08:00AM	Vaccitech to Present at Upcoming September Investor conferences (GlobeNewswire)
Aug-12-21 08:00AM	Vaccitech Reports Second Quarter 2021 Financial Results and Recent Corporate Developments (GlobeNewswire)
Jul-30-21 10:00AM	Vaccitech (NASDAQ:VACC) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jul-08-21 08:00AM	Vaccitech to Present at the William Blair Biotech Focus Conference 2021 (GlobeNewswire) -5.10%
Jul-06-21 10:19AM	Arbutus Biopharma, Vaccitech Team Up To Develop Combo Treatment For Hepatitis B (Benzinga)
07:00AM	Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection (GlobeNewswire)
Jun-20-21 08:00PM	Vaccitech chief confident of beating mRNA in cancer treatment (Financial Times)
Jun-14-21 05:49PM	Vaccitech Reports First Quarter 2021 Financial Results and Recent Corporate Developments (GlobeNewswire)
Jun-01-21 08:00AM	Vaccitech to Present at the Jefferies Virtual Healthcare Conference (GlobeNewswire)

Barinthus Biotherapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. It also focuses on the pipeline of both clinical and preclinical stage therapeutic, and prophylactic programs. The company was founded by Adrian Hill and Dame Sarah Gilbert in March 2021 and is headquartered in Didcot, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Barinthus Biotherapeutics Plc. ADR

Upgrade your FINVIZ experience